Additional amount of milestone have to be made.

No definition available.

Name:	iova_AdditionalMilesonePayable
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

It represents the term of agreement.

+ References

No definition available.

+ Details

Name:	iova_AgreementTerm
Namespace Prefix:	iova_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of clinical trials management fees payable.

+ References

No definition available.

+ Details

Name:	iova_ClinicalTrialsManagementFeesPayable
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

It represents for initial term of licence agreement.

+ References

No definition available.

+ Details

Name:	iova_InitialTermOfLicenceAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

It represent manufacturing and services agreement, amount payable for the reporting period.

+ References

No definition available.

+ Details

Name:	iova_ManufacturingAndServicesAgreementAmountPayable
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of unregistered common stock to be issued.

+ References

No definition available.

+ Details

Name:	iova_NumberOfUnregisteredCommonStockToBeIssued
Namespace Prefix:	iova_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount paid for un-front licence agreement.

+ References

No definition available.

+ Details

Name:	iova_PaymentForUpfrontExclusiveLicense
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents the amount of cash outflow for the payment of clinical trails agreement.

+ References

No definition available.

+ Details

Name:	iova_PaymentsForClinicalTrialsAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents the amount of cash outflow for the payment of upfront licensing fee.

+ References

No definition available.

+ Details

Name:	iova_PaymentsForUpfrontLicensingFee
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents the amount of cash inflow for the refund receipt of clinical trails agreement.

+ References

No definition available.

+ Details

Name:	iova_ProceedsFromRefundOfClinicalTrialsAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of reimbursement will be made in relation to transfer of know-how.

+ References

No definition available.

+ Details

Name:	iova_ReimbursementinRelationToTransferOfKnowhow
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of reversal of prior period expense during the year.

+ References

No definition available.

+ Details

Name:	iova_ReversalOfPriorPeriodExpense
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

+ Details

Name:	us-gaap_PrepaidExpenseCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=iova_ResearchCollaborationAndClinicalGrantAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=iova_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=iova_KarolinskaUniversityHospitalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=iova_NationalCancerInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_MoffittLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_CooperativeResearchAndDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_PolybioceptAbExclusiveAndCoexclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_WuxiApptechIncManufacturingAndServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PropertyPlantAndEquipmentByTypeAxis=iova_ManufacturingSuitesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PropertyPlantAndEquipmentByTypeAxis=iova_CommercialManufacturingCgmpSuiteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_MoffittLicenseAgreementOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_MoffittLicenseAgreementTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSES AND AGREEMENTS (Details Textual) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 14, 2016	Jun. 30, 2018	Apr. 17, 2017	Nov. 30, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2016	May 31, 2017
Research and Development Expense					$ 27,947	$ 16,679	$ 72,410	$ 50,919
Reversal of Prior Period Expense							400
Research and Development Arrangement [Member]
Prepaid Expense, Current										$ 1,400
Research Collaboration and Clinical Grant Agreements [Member]
Research and Development Expense					600	2,000	2,200	4,300
Strategic Alliance Agreement [Member]
Research and Development Expense					100		200
Maximum [Member] \| Research and Development Arrangement [Member]
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross			$ 14,200
Karolinska University Hospital [Member]
Payments For Clinical Trials Agreement									$ 1,600
Proceeds from Refund of Clinical Trials Agreement		$ 1,600
National Cancer Institute [Member]
Research and Development Expense							$ 500
Moffitt License Agreement [Member]
Agreement Term							20 years
Cooperative Research and Development Agreement [Member]
Research and Development Expense					500	500	$ 1,500	1,500
Agreement Term							5 years
PolyBioCept, AB - Exclusive and Co-Exclusive License Agreement [Member]
Research and Development Expense						200		400
Payment For Upfront Exclusive License	$ 2,500
Additional Milesone Payable	$ 8,700
Number Of Unregistered Common Stock To Be Issued	2,219,376
ReimbursementIn Relation To Transfer Of Knowhow	$ 200
Clinical Trials Management Fees Payable	$ 100
Initial Term Of Licence Agreement	30 years
WuXi Apptech, Inc - Manufacturing and Services Agreement [Member]
Research and Development Expense					4,500	$ 3,100	$ 10,600	$ 10,600
WuXi Apptech, Inc - Manufacturing and Services Agreement [Member] \| Manufacturing Suites [Member]
Manufacturing and Services Agreement, Amount Payable				$ 2,500
WuXi Apptech, Inc - Manufacturing and Services Agreement [Member] \| Commercial Manufacturing cGMP Suite [Member]
Manufacturing and Services Agreement, Amount Payable				$ 5,850
Moffitt License Agreement One [Member]
Payments For Upfront Licensing Fee							100
Moffitt License Agreement Two [Member]
Payments For Upfront Licensing Fee							100
Additional Milesone Payable					$ 400		$ 400